Cymbalta
Product Images NDC 52959-892

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 52959-892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by H.j. Harkins Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Cymbalta 01)

Chemical structure of the active ingredient in Cymbalta, showing a chiral molecule with a thiophene group, a naphthalene moiety, and a methylammonium hydrochloride side chain.*

FDA Label Image

Figure 1 (Cymbalta 02)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Cymbalta 60mg BID, Cymbalta 60mg QD, Cymbalta 20mg QD, and placebo. The graph shows trends of patient improvement percentages decreasing as pain improvement percentage increases.*

FDA Label Image

Figure 2 (Cymbalta 03)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Cymbalta 60 mg BID, Cymbalta 60 mg QD, and placebo groups. The Y-axis shows the percentage of patients improved (0 to 100%), and the X-axis shows percent improvement in pain from baseline (0 to 100%). Three lines represent patient improvement trends for each treatment group.*

FDA Label Image

Figure 3 (Cymbalta 13)

A line graph titled with a legend comparing percent improvement in pain from baseline among patients treated with Cymbalta 60 mg twice daily, Cymbalta 60 mg once daily, and placebo. The x-axis shows percent improvement in pain, and the y-axis displays percentage of patients improved, illustrating higher improvement rates for Cymbalta compared to placebo.*

FDA Label Image

Figure 4 (Cymbalta 14)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Cymbalta (CYM) dosages of 20 mg, 60 mg, and 120 mg once daily with placebo. The y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100 percent.*

FDA Label Image

Figure 5 (Cymbalta 15)

A line graph comparing the percentage of patients improved with Cymbalta (60/120 mg once daily) versus placebo across different levels of percent improvement in pain from baseline (BOCF). The X-axis shows percent improvement in pain from 0 to 100%, and the Y-axis indicates the percentage of patients improved, ranging from 0 to 100%. Two curves are shown: one for placebo and one for Cymbalta, with Cymbalta consistently showing higher patient improvement rates.*

FDA Label Image

Figure 6 (Cymbalta 16)

A line graph comparing placebo and Cymbalta 60 mg once daily showing percentage of patients improved vs. percent improvement in pain from baseline. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Cymbalta shows higher patient improvement percentages across most pain improvement levels compared to placebo.*

FDA Label Image

Figure 7 (Cymbalta 17)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for placebo and Cymbalta 120 mg once daily. The vertical axis shows the percentage of patients improved, and the horizontal axis shows percent improvement in pain. The graph features two lines: one for placebo and one for Cymbalta (labeled CYM60/120 mg once daily), illustrating patient response differences.*

FDA Label Image

Package Label- Cymbalta 60 mg, Bottle Of 30 (Cymbalta 60mg Contain 30 T1930)

Label for Cymbalta 60mg delayed-release capsules by H.J. Harkins Company, Inc., originally manufactured by Eli Lilly. The label indicates Lot CYA76EL, expiration 04/12, with a package quantity of 30 capsules. Capsules are green and blue opaque. Includes caution statements and instructions to take as directed by a doctor.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.